Phase 3 Readout
Phase 3 Topline: Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early
- Company
- ELI LILLY & Co (LLY)
- Indication
- Alzheimer's Disease
Other upcoming events for LLY
Phase 2 StartPhase 2 Start: Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Ch
Phase 1 StartPhase 1 Start: A Phase 1, Open-label Study to Assess the Effect of Food on the Pharmacokinetics of Tersolisib Admin
Phase 2 StartPhase 2 Start: Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Os
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef
Phase 1 StartPhase 1 Start: A Phase 1, Single-Blinded, Single-Ascending Dose Study to Evaluate the Safety and Tolerability of a
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.